Click here to preview the new Fast Company

Want to try out the new FastCompany.com?

If you’d like to return to the previous design, click the yellow button on the lower left corner.

25_Genentech

FOR MAKING TARGETED, GENETICS-BASED CANCER THERAPIES

Cancer treatment has been a shock-and-awe affair: Unleash an arsenal on the body and hope the bad cells are killed. Genentech (a division of Swiss pharma giant Roche) is leading a new, sniperlike approach. Last summer, its Zelboraf got FDA approval as the first drug to target and shut down a gene mutation associated with about half of melanoma cases. Analysts expect annual sales to hit $732 million by 2015. "The era of personalized health care is becoming a reality," says Richard Scheller, Genentech's head of research and early development. Genentech has other targeted treatments in the pipeline. Coming soon: a promising drug for breast cancer.

Illustration by Peter Oumanski

Add New Comment

0 Comments